Ascendis Pharma A/S (NASDAQ:ASND) Price Target Lowered to $153.00 at TD Cowen

Ascendis Pharma A/S (NASDAQ:ASND) had its price target lowered by TD Cowen from $160.00 to $153.00 in a research note published on Friday,Benzinga reports. The firm currently has a buy rating on the biotechnology company’s stock.

Other equities analysts have also issued reports about the stock. Bank of America upped their price objective on shares of Ascendis Pharma A/S from $175.00 to $191.00 and gave the stock a “buy” rating in a report on Monday, September 23rd. Wedbush restated an “outperform” rating and set a $181.00 price target on shares of Ascendis Pharma A/S in a research report on Friday. Evercore ISI boosted their price objective on Ascendis Pharma A/S from $191.00 to $205.00 and gave the company an “outperform” rating in a report on Tuesday, September 17th. Citigroup raised their target price on Ascendis Pharma A/S from $178.00 to $207.00 and gave the company a “buy” rating in a report on Tuesday, September 17th. Finally, Stifel Nicolaus boosted their price target on shares of Ascendis Pharma A/S from $200.00 to $207.00 and gave the stock a “buy” rating in a research note on Friday. One analyst has rated the stock with a sell rating, one has issued a hold rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $191.77.

Ascendis Pharma A/S Stock Up 1.8 %

NASDAQ:ASND opened at $126.51 on Friday. The company has a market capitalization of $7.67 billion, a P/E ratio of -15.66 and a beta of 0.66. Ascendis Pharma A/S has a 52 week low of $90.13 and a 52 week high of $161.00. The stock’s fifty day moving average is $132.30 and its two-hundred day moving average is $132.60.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings data on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The company had revenue of $38.75 million for the quarter, compared to analysts’ expectations of $94.74 million. Sell-side analysts anticipate that Ascendis Pharma A/S will post -7.3 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Signaturefd LLC raised its holdings in shares of Ascendis Pharma A/S by 13.2% in the 3rd quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock valued at $102,000 after purchasing an additional 80 shares in the last quarter. Profund Advisors LLC lifted its holdings in Ascendis Pharma A/S by 3.0% during the 2nd quarter. Profund Advisors LLC now owns 2,919 shares of the biotechnology company’s stock worth $398,000 after buying an additional 85 shares during the last quarter. Rhumbline Advisers boosted its position in shares of Ascendis Pharma A/S by 10.3% during the 2nd quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock worth $209,000 after acquiring an additional 143 shares in the last quarter. Thrivent Financial for Lutherans increased its holdings in shares of Ascendis Pharma A/S by 0.3% in the 3rd quarter. Thrivent Financial for Lutherans now owns 78,473 shares of the biotechnology company’s stock valued at $11,717,000 after acquiring an additional 228 shares during the last quarter. Finally, Avior Wealth Management LLC raised its position in shares of Ascendis Pharma A/S by 3.0% during the 3rd quarter. Avior Wealth Management LLC now owns 8,212 shares of the biotechnology company’s stock worth $1,226,000 after acquiring an additional 240 shares in the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.